Oral bioavailability is variable between people. Some people absorb well; others absorb poorly. That inter-individual variation is larger than with injectables and is one reason the trial data for oral formulations receives different treatment.
Topic summary
Why fasting instructions for oral semaglutide are not optional advice — does this still hold?
This is a generated summary. It shows the 9 most-liked posts from a topic of 107, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
Research-use-only oral material is not a licensed tablet and there is no reason to assume it carries a functioning absorption-enhancement system at all. The formulation is most of the product here.
Posted with less confidence than the sentence structure implies.
33 likes 15mo
m.vukovic, post #1: Asking directly, because I could not find a straight answer: Why fasting instructions for oral semaglutide are not optional advice — does this still hold? A methods question rather than a substantive one, about fasting instructions for oral semaglutide. Everyone quotes the same figure and I cannot find anyone who says how it was arrived… Go to post
Adding the measurement that post #33 says would settle it.
Missed doses behave differently for a daily oral than for a weekly injection. With a short interval you are near a trough rather than perturbing a slowly moving average, and the labelling reflects that.
k.pereira, post #32: SNAC is the sodium N-(8-[2-hydroxybenzoyl]amino) caprylate, an absorption enhancer that transiently raises local pH in the stomach and promotes gastric mucosal absorption. Without it, oral bioavailability of semaglutide would be too low for clinically useful dosing. It is one reading of the data and not the only reasonable one. Go to post
I had written a reply contradicting post #40 and deleted it. Here is what survived.
Orforglipron is a small molecule, not a peptide. That changes almost everything: no absorption enhancer required, no fasting window, chemical synthesis instead of peptide synthesis, different analytical methods entirely. Data from peptide agonists does not transfer.
I would treat that as a working assumption and revisit it.
m.vukovic, post #1: Asking directly, because I could not find a straight answer: Why fasting instructions for oral semaglutide are not optional advice — does this still hold? A methods question rather than a substantive one, about fasting instructions for oral semaglutide. Everyone quotes the same figure and I cannot find anyone who says how it was arrived… Go to post
Post #64 is right about the mechanism and I think understates the practical bit.
Why an oral formulation is a formulation achievement: the molecule is the same but the tablet is novel. Getting a peptide across the gastric epithelium at usable bioavailability is a chemistry problem, not a dose problem.
Where I part company with post #73, and it is a narrow parting.
The absorption enhancer in the licensed oral product works by transiently raising local gastric pH and promoting absorption across the mucosa. It is the reason the fasting and water-volume instructions are specific rather than cautious.
It cost nothing to check and would have cost something not to.
29 likes 12mo
I had written a reply contradicting post #80 and deleted it. Here is what survived.
Orforglipron is a small molecule, not a peptide. That changes almost everything: no absorption enhancer required, no fasting window, chemical synthesis instead of peptide synthesis, different analytical methods entirely. Data from peptide agonists does not transfer.
I would be interested in a counterexample if anyone has one.
32 likes 11mo
Oral semaglutide's bioavailability is low and variable, which is why the dose numbers are an order of magnitude different from the injectable. That is a formulation consequence and not a difference in potency.
30 likes 11mo
Read the full topic (107 posts)
This topic was referenced in
- SNAC and the mechanism of oral peptide absorptionCompounds › Oral incretins · 17 replies
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Oral semaglutide bioavailability and its variability between people
Posting this under the heading it deserves: Oral semaglutide bioavailability and its variability between people Everything below is what sits behind that. I would like to know what people here actually do…
|
+44 | 48 | 574 | 3mo |
|
Dose numbers for oral formulations are not comparable to injectable ones — a second dataset
Dose numbers for oral formulations are not comparable to injectable ones — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. Posting a small dataset on Dose…
|
+48 | 52 | 59k | 18mo |
|
Why oral semaglutide needs an absorption enhancer at all
Why oral semaglutide needs an absorption enhancer at all I have a specific reason for asking rather than idle curiosity, and the context is below. Reading back through what has been written here about oral…
|
+59 | 65 | 61k | 7mo |
|
Why oral semaglutide needs an absorption enhancer at all — what changed since
Asking directly, because I could not find a straight answer: Why oral semaglutide needs an absorption enhancer at all — what changed since What changes if the standard account of oral semaglutide is wrong? I…
|
2 | 61k | 14mo | |
|
SNAC and the mechanism of oral peptide absorption — the long version
SNAC and the mechanism of oral peptide absorption — the long version Writing it up because I had to work it out twice and would rather nobody else did. Question about what the published evidence for this…
|
+32 | 36 | 6.8k | 16mo |
Related topics — sharing the tags orforglipron, SOUL trial, PIONEER programme
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Is "synergy" the right word for the combination data?
Is "synergy" the right word for the combination data? — that is the question, and I have not found it answered plainly anywhere I have looked. Setting out what I think I know about this compound and asking…
|
+5 | 9 | 13k | 25d |
|
Follow-up: Open-label extensions: what survives and what does not
Open-label extensions: what survives and what does not — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin Open-label extensions down and I want to set…
|
+22 | 26 | 397 | 16mo |
|
Reading SURMOUNT-1 without the press release — one year on
Reading SURMOUNT-1 without the press release — one year on — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on Reading SURMOUNT-1…
|
+45 | 50 | 7.6k | 5mo |
|
Run-in periods and the population they select
On the subject in the title: Run-in periods and the population they select Working notes rather than a conclusion. An honest uncertainty about run-in periods rather than a disguised assertion. I do not know…
|
+130 | 142 | 7.3k | 1mo |
|
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version
On the subject in the title: Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version Working notes rather than a conclusion. A narrow question about Tirzepatide in type 2…
|
+85 | 90 | 13k | 7mo |